284 related articles for article (PubMed ID: 18095923)
1. Update: vildagliptin for the treatment of Type 2 diabetes.
Garber AJ; Sharma MD
Expert Opin Investig Drugs; 2008 Jan; 17(1):105-13. PubMed ID: 18095923
[TBL] [Abstract][Full Text] [Related]
2. Vildagliptin: a review of its use in type 2 diabetes mellitus.
Keating GM
Drugs; 2010 Nov; 70(16):2089-112. PubMed ID: 20964454
[TBL] [Abstract][Full Text] [Related]
3. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus.
Croxtall JD; Keam SJ
Drugs; 2008; 68(16):2387-409. PubMed ID: 18973400
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
Mikhail N
Vasc Health Risk Manag; 2008; 4(6):1221-7. PubMed ID: 19337535
[TBL] [Abstract][Full Text] [Related]
5. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
Gupta R; Walunj SS; Tokala RK; Parsa KV; Singh SK; Pal M
Curr Drug Targets; 2009 Jan; 10(1):71-87. PubMed ID: 19149538
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
[TBL] [Abstract][Full Text] [Related]
7. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N
Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
[TBL] [Abstract][Full Text] [Related]
8. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
Bolli G; Dotta F; Colin L; Minic B; Goodman M
Diabetes Obes Metab; 2009 Jun; 11(6):589-95. PubMed ID: 19515179
[TBL] [Abstract][Full Text] [Related]
9. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
Filozof C; Gautier JF
Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
Lukashevich V; Del Prato S; Araga M; Kothny W
Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.
Del Prato S
Int J Clin Pract Suppl; 2007 Aug; (154):38-48. PubMed ID: 17593276
[TBL] [Abstract][Full Text] [Related]
12. Vildagliptin: a review of its use in type 2 diabetes mellitus.
Keating GM
Drugs; 2014 Apr; 74(5):587-610. PubMed ID: 24638989
[TBL] [Abstract][Full Text] [Related]
13. Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes.
Prescrire Int; 2008 Oct; 17(97):188. PubMed ID: 19534040
[No Abstract] [Full Text] [Related]
14. Translating science into clinical practice: focus on vildagliptin in combination with metformin.
Barnett AH
Diabetes Obes Metab; 2009 May; 11 Suppl 2():18-26. PubMed ID: 19385980
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.
Serra D; He YL; Bullock J; Riviere GJ; Balez S; Schwartz S; Wang Y; Ligueros-Saylan M; Jarugula V; Dole WP
Int J Clin Pharmacol Ther; 2008 Jul; 46(7):349-64. PubMed ID: 18793589
[TBL] [Abstract][Full Text] [Related]
16. Vildagliptin monotherapy. To be avoided, like other DPP-4 inhibitors.
Prescrire Int; 2013 May; 22(138):121. PubMed ID: 23819170
[No Abstract] [Full Text] [Related]
17. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.
Garber AJ; Foley JE; Banerji MA; Ebeling P; Gudbjörnsdottir S; Camisasca RP; Couturier A; Baron MA
Diabetes Obes Metab; 2008 Nov; 10(11):1047-56. PubMed ID: 18284434
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment.
Kanazawa I; Tanaka KI; Notsu M; Tanaka S; Kiyohara N; Koike S; Yamane Y; Tada Y; Sasaki M; Yamauchi M; Sugimoto T
Diabetes Res Clin Pract; 2017 Jan; 123():9-17. PubMed ID: 27914297
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
Hassanein M; Abdallah K; Schweizer A
Vasc Health Risk Manag; 2014; 10():319-26. PubMed ID: 24920915
[TBL] [Abstract][Full Text] [Related]
20. Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin.
Schweizer A; Foley JE; Kothny W; Ahrén B
Vasc Health Risk Manag; 2013; 9():57-64. PubMed ID: 23431062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]